Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175

Gallay, Philippe; Chatterji, Udayan; Bobardt, Michael; Long, Zhe; Zhang, S.; Zhuang, Songlin

doi:10.1016/s0168-8278(16)00649-8

Search citation statements

Order By: Relevance

Paper Sections

Select...

Challenges and Future Direction Of Daa1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2017

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study showed promising results in the possible incorporation of a new cyclophilin inhibitor, STG-175 in DAA-regimen. [46] …”

Section: Challenges and Future Direction Of Daamentioning

confidence: 99%

Direct acting anti-hepatitis C virus drugs: Clinical pharmacology and future direction

Geddawy

Ibrahim

Elbahie

et al. 2017

Journal of Translational Internal Medicine

151

103

View full text Add to dashboard Cite

Chronic hepatitis C virus (HCV) infection is a leading cause of chronic liver disease. The introduction of direct acting antiviral agents (DAAs) for its treatment represents a major advance in terms of sustained virologic response (SVR) rates and adverse effect profiles. Mechanistically, DAAs inhibit specific HCV non-structural proteins (NS) that are vital for its replication. Boceprevir, telaprevir, simeprevir, asunaprevir, grazoprevir and paritaprevir are NS3/4A inhibitors. Ombitasvir, ledipasvir, daclatasvir, elbasvir and velpatasvir are NS5A inhibitors. Sofosbuvir and dasabuvir are NS5B inhibitors. Currently, a combination of two or more DAAs is the corner stone for the treatment of HCV infection. However, the success of DAA therapy is facing several challenges, including the potential of drug-drug interactions and resistant variance. Moreover, the shortage of relevant clinical pharmacological data and drug interaction regarding DAA is a clinical concern. The present review discusses the clinical pharmacology of DAAs with special emphasis on drug-drug interaction.

show abstract

“…A recent study showed promising results in the possible incorporation of a new cyclophilin inhibitor, STG-175 in DAA-regimen. [46] …”

Section: Challenges and Future Direction Of Daamentioning

confidence: 99%

Direct acting anti-hepatitis C virus drugs: Clinical pharmacology and future direction

Geddawy

Ibrahim

Elbahie

et al. 2017

Journal of Translational Internal Medicine

151

103

View full text Add to dashboard Cite

show abstract

Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175

Cited by 1 publication

References 52 publications

Direct acting anti-hepatitis C virus drugs: Clinical pharmacology and future direction

Direct acting anti-hepatitis C virus drugs: Clinical pharmacology and future direction

Contact Info

Product

Resources

About